Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Ohmefentanyl
- DrugBank Accession Number
- DB01570
- Background
Ohmefentanyl is an extremely potent opioid analgesic drug which selectively binds to the µ-opioid receptor. The Chinese have recorded ohmefentanyl as having a potency that is 6,300 times morphine. Ohmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids such as carfentanil and etorphine which are used for tranquilizing large animals such as elephants in veterinary medicine. In mice, ohmefentanyl was 28 times more powerful than fentanyl and 6300 times more effective than morphine. Ohmefentanyl has three stereogenic centers and hence, it can derive into eight stereoisomers, currently named F9201–F9208. Researchers are studying the different pharmaceutical properties of these isomers.
- Type
- Small Molecule
- Groups
- Illicit
- Structure
Structure for Ohmefentanyl (DB01570)
- Weight
- Average: 366.4965
Monoisotopic: 366.230728214 - Chemical Formula
- C23H30N2O2
- Synonyms
- Beta-hydroxy-3-methylfentanyl
- OMF
- β-hydroxy-3-methylfentanyl
- External IDs
- RTI-4614-4
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as fentanyls. These are compounds containing the fentanyl moiety or a derivative, which is based on a N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide skeleton.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Piperidines
- Sub Class
- Fentanyls
- Direct Parent
- Fentanyls
- Alternative Parents
- Anilides / Aralkylamines / Tertiary carboxylic acid amides / Trialkylamines / Secondary alcohols / Amino acids and derivatives / 1,2-aminoalcohols / Azacyclic compounds / Organopnictogen compounds / Organic oxides show 3 more
- Substituents
- 1,2-aminoalcohol / Alcohol / Amine / Amino acid or derivatives / Anilide / Aralkylamine / Aromatic alcohol / Aromatic heteromonocyclic compound / Azacycle / Benzenoid show 16 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Y8263089ZX
- CAS number
- 78995-14-9
- InChI Key
- FRPRNNRJTCONEC-UHFFFAOYSA-N
- InChI
- InChI=1S/C23H30N2O2/c1-3-23(27)25(20-12-8-5-9-13-20)21-14-15-24(16-18(21)2)17-22(26)19-10-6-4-7-11-19/h4-13,18,21-22,26H,3,14-17H2,1-2H3
- IUPAC Name
- N-[1-(2-hydroxy-2-phenylethyl)-3-methylpiperidin-4-yl]-N-phenylpropanamide
- SMILES
- CCC(=O)N(C1CCN(CC(O)C2=CC=CC=C2)CC1C)C1=CC=CC=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 62279
- PubChem Substance
- 46507925
- ChemSpider
- 56080
- BindingDB
- 50033531
- ChEMBL
- CHEMBL333410
- Wikipedia
- Ohmefentanyl
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0871 mg/mL ALOGPS logP 3.12 ALOGPS logP 3.38 Chemaxon logS -3.6 ALOGPS pKa (Strongest Acidic) 14.11 Chemaxon pKa (Strongest Basic) 8.59 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 43.78 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 109.11 m3·mol-1 Chemaxon Polarizability 42.37 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9859 Blood Brain Barrier + 0.8166 Caco-2 permeable + 0.6217 P-glycoprotein substrate Substrate 0.7502 P-glycoprotein inhibitor I Inhibitor 0.8878 P-glycoprotein inhibitor II Inhibitor 0.667 Renal organic cation transporter Non-inhibitor 0.6416 CYP450 2C9 substrate Non-substrate 0.7609 CYP450 2D6 substrate Non-substrate 0.6912 CYP450 3A4 substrate Substrate 0.6818 CYP450 1A2 substrate Non-inhibitor 0.858 CYP450 2C9 inhibitor Non-inhibitor 0.8491 CYP450 2D6 inhibitor Non-inhibitor 0.589 CYP450 2C19 inhibitor Non-inhibitor 0.8011 CYP450 3A4 inhibitor Non-inhibitor 0.6046 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7374 Ames test Non AMES toxic 0.8161 Carcinogenicity Non-carcinogens 0.8433 Biodegradation Not ready biodegradable 0.7959 Rat acute toxicity 2.7242 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8868 hERG inhibition (predictor II) Inhibitor 0.5691
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-014l-0049000000-54d6e48a9d9de5f26d21 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0019000000-d5238689ebf980679455 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-0093000000-1ee331e32dafd749f8b0 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-6193000000-436684a14d47063f1c0a Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-1291000000-de86b27b832543d1d787 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-2493000000-ecff37185a077c7f33a1 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 183.5296 predictedDeepCCS 1.0 (2019) [M+H]+ 185.88759 predictedDeepCCS 1.0 (2019) [M+Na]+ 193.02559 predictedDeepCCS 1.0 (2019)
Drug created at July 31, 2007 13:10 / Updated at June 12, 2020 16:51